Poolbeg Pharma PLC (AIM:POLB) principal scientist Liam Tremble joined Proactive's Stephen Gunnion to discuss the first site activation for Poolbeg's POLB 001 TOPICAL clinical trial, evaluating the drug as a preventative treatment for cytokine release syndrome (CRS), a serious side effect linked to CAR-T and bispecific antibody therapies. The UK study will enrol 30 multiple myeloma patients receiving teclistamab, with early readouts expected due to CRS typically occurring within the first two weeks of treatment.
Tremble also highlighted new data presented at the EHA Congress showing POLB 001 reduced inflammatory cytokines without compromising tumour-killing activity, alongside early research suggesting potential applications in acute myeloid leukaemia (AMS).
For more interviews and market insights, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future content.
#PoolbegPharma #POLB001 #Biotech #MultipleMyeloma #AML #AcuteMyeloidLeukemia #CancerResearch #Immunotherapy #CRS #CytokineReleaseSyndrome #Teclistamab #BloodCancer #ClinicalTrials #EHA2026 #HealthcareInnovation
